Anti-Human IL5RA Recombinant Antibody (TAB-222)

Customer Review

There are currently no Customer reviews or questions for TAB-222. Click the button above to contact us or submit your feedback about this product.

Sarah Johnson
13.Mar,23

Ideal for IL5RA Research

The Anti-Human IL5RA Therapeutic Antibody (Benralizumab) has been a fantastic addition to our IL5RA studies. Its specificity and sensitivity are outstanding, consistently providing clear results. This antibody has become essential for our research, improving the accuracy and reliability of our assays.

Brian Martinez
18.Jul,22

Reliable for Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for IL5RA is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Megan Thompson
11.Aug,21

Consistent and Effective

This antibody has proven to be consistent and effective in our various assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for IL5RA have been particularly beneficial.

Q&As

1. Is the anti-Human IL5RA therapeutic antibody Benralizumab suitable for use in flow cytometry?

   A: Yes, the anti-Human IL5RA therapeutic antibody Benralizumab (TAB-222) is suitable for use in flow cytometry. It is designed to specifically bind to IL5RA, making it suitable for detecting IL5RA-expressing cells in flow cytometry.

2. What are the storage recommendations for the anti-Human IL5RA therapeutic antibody Benralizumab?

   A: The recommended storage condition for the anti-Human IL5RA therapeutic antibody Benralizumab (TAB-222) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human IL5RA therapeutic antibody Benralizumab be used in immunoprecipitation assays?

   A: Yes, the anti-Human IL5RA therapeutic antibody Benralizumab (TAB-222) can be used in immunoprecipitation assays. It provides specific binding to IL5RA, enabling the successful precipitation of the target protein from complex mixtures.

4. Is this anti-Human IL5RA therapeutic antibody Benralizumab effective in ELISA applications?

   A: Yes, the anti-Human IL5RA therapeutic antibody Benralizumab (TAB-222) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of IL5RA.

5. What is the optimal dilution for using the anti-Human IL5RA therapeutic antibody Benralizumab in Western blot?

   A: The optimal dilution for using the anti-Human IL5RA therapeutic antibody Benralizumab (TAB-222) in Western blot is typically 1:500 to 1:2000. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Calzetta, Luigino, et al. "Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab." British Journal of Pharmacology 177.20 (2020): 4750-4765. https://doi.org/10.1111/bph.15240
   This study investigates the effectiveness of targeting the IL-5 pathway in addressing airway hyperresponsiveness (AHR) in asthma by comparing two monoclonal antibodies, benralizumab and mepolizumab. The research focuses on their ability to modulate AHR in human airways passively sensitized to mimic asthmatic conditions. The study measures the inhibition of AHR to histamine, parasympathetic activation, and mechanical stress, as well as the modulation of cyclic AMP (cAMP) levels. The results demonstrate that both benralizumab and mepolizumab significantly reduce AHR, with benralizumab being more potent. The study concludes that targeting the IL-5/IL-5Rα axis is an effective strategy for preventing AHR.
   Creative Biolabs provided the benralizumab (Cat# TAB-222) and mepolizumab (Cat# TAB-031) used in this study. These antibodies were essential for the comparative analysis of their effects on AHR and cAMP levels in human bronchial tissues. The use of these reagents allowed the researchers to determine the differential potency and efficacy of benralizumab and mepolizumab in modulating AHR, thus contributing significantly to the understanding of their therapeutic potential in treating asthma.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-222, RRID: AB_3111882)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Benralizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Benralizumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "IL5RA"

Select a product category from the dropdown menu below to view related products.